Farmas USA

Tecnología biogenética CRISPR

Las empresas aún no son públicas. Cuando salgan a bolsa hay que correr a pillarlas

10 ways the biotech discovery of the century is poised to change our bodies and minds
http://www.businessinsider.com/genes-that-make-you-stronger-and-healthier-2015-3#ixzz3Upk0kHkw

Biotech Startup Editas Medicine Wants to Cure Grievous Genetic Diseases with New Genome Editing Technology | MIT Technology Review

http://www.technologyreview.com/news/522051/new-genome-editing-method-could-make-gene-therapy-more-precise-and-effective/

Double CRISPR deals for Novartis
http://www.european-biotechnology-news.com/news/news/2015-01/double-crispr-deals-for-novartis.html

THLD

Threshold Pharmaceuticals to Present Data Supporting Planned Phase 2 Trials of TH-4000, a Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor

Data to Be Presented on TH-4000 and Evofosfamide at the AACR Annual Meeting 2015

http://investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=902417

FOLD

Felicidades a los premiados

Migalastat FDA approval filing in 2H '15; EU filing in Q2.

http://www.thestreet.com/story/13084249/1/amicus-accelerates-approval-filing-plans-for-rare-disease-drug.html

http://files.shareholder.com/downloads/AMTX/4122799195x0x816776/218c56dc-f3f9-4d5f-8753-39ecf107cbe2/FOLD_News_2015_3_19_General.pdf

NVAX.

Vaya, vaya ... jueguecitos con gaps de apertura a la baja ... de nuevo están meneando el arbolico, eh? Hoy hasta los 9,25 , ayer hasta los 9,22 ... descarado el intento reiterado de levantar los stops ... de los incautos que aun los ponen. 

Pero quién webs pondrá stops en ésta? Si siempre hace la misma jugada en la apertura.
NVAX

CLSN

Celsion is financially stable for the next 2 years.
The obvious binary event is ASCO, but clinical evidence tilts the odds in favor of a positive catalyst.
The market ignored an announcement that says Celsion could be in the business of selling ThermoDox® 3 years before approval.

In January, Celsion entered into an agreement with myTomorrows to implement an Early Access Program (EAP) for ThermoDox® for patients with RCWBC. EAPs allow eligible patients in all countries of the European Union territory plus Switzerland ethical access to investigational medicines for unmet medical needs. Celsion expects to have ThermoDox® available for the EAP in Q2 2015 at competitive commercial prices. The point is not really to beat the analyst Q2 estimates, which will likely be revised upward as Q2 approaches, but that Celsion will have income as if they have a product on the market. This EAP revenue, no matter how small, will instantly make Celsion more valuable, and the Q1 report may provide clues as to how much more.

http://seekingalpha.com/article/3010936-celsion-corporation-has-significant-upside-in-q2-with-an-unexpected-income-source?app=1&auth_param=7ib4d:1agjcbf:345d4b0fb6d07ac01d6de51fb840ed21&uprof=44

TGTX

Me parece que ha salido en Cramer y le ha dado impulso (no lo he confirmado). Y $heff la persigue para meterle. Yo también...

Los day traders que se mueven por puro tecnico, por ejemplo.